Vir Biotechnology, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $68.6M | $74.2M | $86.2M | $1.62B | $1.10B | $76.4M | $8.1M | $10.7M |
| Cost of Revenue | $26.0K | $845.0K | $2.8M | $146.3M | $65.9M | $0 | $0 | — |
| Gross Profit | $68.5M | $73.4M | $83.4M | $1.47B | $1.03B | $76.4M | $8.1M | — |
| Gross Margin | 100.0% | 98.9% | 96.8% | 90.9% | 94.0% | 100.0% | 100.0% | — |
| Operating Expenses | ||||||||
| Research & Development | $456.0M | $506.5M | $579.7M | $474.6M | $448.0M | $302.4M | $148.5M | $100.2M |
| SG&A Expense | $92.1M | $119.0M | $174.4M | $161.8M | $160.8M | $70.9M | $37.6M | $29.1M |
| Operating Income | $-479.3M | $-587.2M | $-684.3M | $833.1M | $420.8M | $-297.0M | $-178.0M | $-118.7M |
| Operating Margin | -699.2% | -791.3% | -794.0% | 51.6% | 38.4% | -388.9% | -2,199.7% | -1,112.6% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-437.8M | $-523.1M | $-628.2M | $754.3M | $549.8M | $-298.6M | $-174.5M | $-116.4M |
| Income Tax Expense | $217.0K | $-1.1M | $-13.1M | $238.4M | $21.2M | $54.0K | $154.0K | $-480.0K |
| Net Income | $-438.0M | $-522.0M | $-615.1M | $515.8M | $528.6M | $-298.7M | $-174.7M | $-115.9M |
| Net Margin | -638.9% | -703.4% | -713.7% | 31.9% | 48.3% | -391.1% | -2,159.0% | -1,086.3% |
| EPS (Basic) | $-3.16 | $-3.83 | $-4.59 | $3.89 | $4.07 | $-2.51 | $-1.44 | $-3.78 |
| EPS (Diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-1.44 | $-3.78 |
| Shares Outstanding (Basic) | 138.5M | 136.2M | 134.1M | 132.6M | 129.9M | 119.2M | 121.4M | 35.4M |
| Shares Outstanding (Diluted) | 138.5M | 136.2M | 134.1M | 134.8M | 133.4M | 119.2M | 121.4M | 35.4M |
| Dividends Per Share | — | — | — | — | — | — | — | — |